Author argues Herbal Dispatch is undervalued because its global export pivot builds recurring revenue independent of uncertain U.S. Schedule III rescheduling.
Unpriced research observations (excluded from Calls and Returns):
HERB — LONG The author argues Herbal Dispatch is positioned for growth independent of U.S. catalysts because it is building recurring revenue through exports to federally legal markets like Australia, Portugal, Germany, Brazil and Czech Republic, with plans to triple volumes by 2028 and add new markets. The stated mechanism is diversification and revenue momentum now rather than betting on uncertain U.S. Schedule III timelines, supported by GMP/EU-GMP compliance, a recent OTCQB upgrade and a record $4.1M October 2025 Canadian e-commerce base. The author notes the low ~CA$5-7M market cap as part of the opportunity. No explicit risk is stated beyond the U.S. timeline uncertainty being avoided. resolved_asset_type_mismatch
This global pivot provides diversification and revenue momentum now, rather than betting on uncertain U.S. timelines.